The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,357.00
Bid: 1,343.00
Ask: 1,347.00
Change: 29.00 (2.18%)
Spread: 4.00 (0.298%)
Open: 1,331.00
High: 1,358.00
Low: 1,299.00
Prev. Close: 1,328.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Court Approval Concludes Antitrust MDL

29 Feb 2024 07:00

RNS Number : 8632E
Indivior PLC
29 February 2024
 

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m. On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims. This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in?the United States?in?Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit?www.indivior.com?to learn more. Connect with Indivior on LinkedIn by visiting?www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDDBXDDGSI
Date   Source Headline
26th May 20227:00 amRNSTransaction in Own Shares
25th May 20227:00 amRNSTransaction in Own Shares
24th May 20229:00 amRNSIndivior to Participate in Conference
24th May 20227:00 amRNSTransaction in Own Shares
23rd May 202210:22 amRNSHolding(s) in Company
23rd May 20227:00 amRNSTransaction in Own Shares
20th May 20227:00 amRNSTransaction in Own Shares
19th May 20227:00 amRNSTransaction in Own Shares
18th May 202210:08 amRNSDirector Declaration
18th May 20227:00 amRNSTransaction in Own Shares
17th May 202212:32 pmRNSHolding(s) in Company
17th May 20227:00 amRNSTransaction in Own Shares
16th May 20227:00 amRNSTransaction in Own Shares
13th May 20227:00 amRNSTransaction in Own Shares
12th May 20227:00 amRNSTransaction in Own Shares
11th May 20227:00 amRNSTransaction in Own Shares
10th May 202210:59 amRNSBlock listing Interim Review
10th May 20227:00 amRNSTransaction in Own Shares
9th May 20227:00 amRNSTransaction in Own Shares
6th May 20227:00 amRNSTransaction in Own Shares
5th May 20222:55 pmRNSResult of AGM
5th May 20227:00 amRNSTransaction in Own Shares
4th May 20227:00 amRNSTransaction in Own Shares
3rd May 20227:00 amRNSShare Repurchase Program
28th Apr 20227:00 amRNS1st Quarter Results
27th Apr 20227:00 amRNSAppointment of Independent Non-Executive Director
25th Apr 20225:18 pmRNSCommittee Change
7th Apr 202210:30 amRNSNotice of Q1 Results
1st Apr 202210:05 amRNSTotal Voting Rights
31st Mar 20222:00 pmRNSIndivior to Commence Consultations
30th Mar 20223:16 pmRNSAnnual Report and Accounts and Notice of AGM
16th Mar 20221:04 pmRNSDirector/PDMR Shareholding
15th Mar 20221:00 pmRNSDirector/PDMR Shareholding
15th Mar 20221:00 pmRNSDirector/PDMR Shareholding
8th Mar 20221:56 pmRNSDirector/PDMR Shareholding
2nd Mar 202212:22 pmRNSDirector/PDMR Shareholding
18th Feb 202212:10 pmRNSDirector/PDMR Shareholding
16th Feb 20227:00 amRNSFinal Results
1st Feb 202211:41 amRNSTotal Voting Rights
1st Feb 20229:23 amRNSNotice of Results
28th Jan 20227:00 amRNSBuprenorphine-Fentanyl Interaction Study Results
4th Jan 202210:53 amRNSTotal Voting Rights
29th Dec 20211:00 pmRNSTransaction in Own Shares
24th Dec 20217:00 amRNSTransaction in Own Shares
23rd Dec 20217:00 amRNSTransaction in Own Shares
22nd Dec 20217:00 amRNSTransaction in Own Shares
21st Dec 20217:00 amRNSTransaction in Own Shares
20th Dec 20217:00 amRNSTransaction in Own Shares
17th Dec 20217:00 amRNSTransaction in Own Shares
16th Dec 20217:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.